As a leader in the application of Hydrogen/Deuterium-Exchange Mass Spectrometry technology, ExSAR provides H/D-Ex technology services to third parties. In this capacity, ExSAR offers epitope mapping services in support of monoclonal therapeutic antibody development. ExSAR also employs H/D-Ex to characterize proteins, including biosimilars and to identify ligand binding sites, typically in conjunction with fragment based drug discovery programs.